1 recruiting. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Previously Untreated Relapsed Refractory Acute Myeloid Leukemia: new trials by email Literature Review of Previously Untreated Relapsed Refractory Acute Myeloid Leukemia trials Research Report on Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Biomarker-Based Treatment of Acute Myeloid Leukemia Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis - Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | Phase 2 / Phase 3 | Recruiting | Beat AML, LLC | 3000 | 2016-11-01 | 2026-09-03 |
6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine (1) · AZD5153 (1) · AZD5991 (1) · Azacitidine (1) · BI 836858 (1) · Cytarabine (1) · Daunorubicin (1) · Decitabine (1) · Idarubicin (1) · dubermatinib (1) · enasidenib (1) · ficlatuzumab (1) · gilteritinib (1) · ivosidenib (1) · pevonedistat (1)
Beat AML, LLC (1)
United States (1)
Alice Mims, MD (1)